about
Mitochondria: a new therapeutic target in chronic kidney diseaseSerum metabolomic profiling and incident CKD among African AmericansRole of carnitine in diseaseEffects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial.Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients.L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function.L-carnitine improves the asthma control in children with moderate persistent asthma.Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to DialysisA pharmacokinetic model for L-carnitine in patients receiving haemodialysisToward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprintPharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis.L-carnitine supplementation in the dialysis population: are Australian patients missing out?A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.Pharmacologic Treatment of Common Symptoms in Dialysis Patients: A Narrative Review.The effects of oral L-carnitine supplementation on physical capacity and lipid metabolism in chronic hemodialysis patients.Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction.Hemodynamic stabilizing effects of L-carnitine in chronic hemodialysis patients.
P2860
Q26776397-36462183-C2CE-40C0-A953-82941886E0BFQ34008968-5A1CBF19-B0D5-44BF-A701-53777063BC1EQ34618777-5AA44D8F-D6AA-48E6-AF56-3A11A21F842EQ34775121-45C6A8DE-3977-4415-872A-5DF3CC9968D6Q35232132-CAEAC6DA-7FC2-43D8-93ED-67ACD4E14779Q35580023-007F356A-7FC0-4375-A9FA-A469595BA405Q35585263-6D8B5476-C1FF-4A55-8D95-EF51042BD853Q35748583-437420DF-4C00-49BC-B576-696C1B9FFBB1Q36024680-71DC057F-8B7B-4CF8-88FD-8C3A509251E2Q36162746-EE0F01CF-0BAD-4B19-9475-B281410822F9Q36271076-22DD7E27-E2FE-4E9E-A7CD-DC6D33EBEAAFQ37058531-E1F52C09-67F0-46B7-B7A8-F9AEB88DF73DQ38171391-9A41CAD9-005B-4B04-931A-3B13488EB5A8Q38442886-0C73B7AC-DD5D-4E7B-94CE-477B70563DA0Q38962297-64005C61-AA90-445D-BA0F-443A0954CCB5Q41239162-17297E08-EDE7-4244-B300-9CAEE7DCF857Q41857235-398051CF-E186-4EDA-8B93-FB237AF764DE
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
L-carnitine in dialysis patients.
@ast
L-carnitine in dialysis patients.
@en
L-carnitine in dialysis patients.
@nl
type
label
L-carnitine in dialysis patients.
@ast
L-carnitine in dialysis patients.
@en
L-carnitine in dialysis patients.
@nl
prefLabel
L-carnitine in dialysis patients.
@ast
L-carnitine in dialysis patients.
@en
L-carnitine in dialysis patients.
@nl
P1433
P1476
L-carnitine in dialysis patients.
@en
P2093
P304
P356
10.1046/J.1525-139X.2001.00055.X
P577
2001-05-01T00:00:00Z